SHYAMAL K. SANYAL, F.A.A.P., F.A.C.C.; WARREN W. JOHNSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The recent article by Bristow and colleagues (Ann Intern Med 88:168-175, 1978) advocating the routine use of right endomyocardial biopsy in patients receiving doxorubicin raises several questions.
In their study a scoring system based on the ultrastructural characteristics of myocytes was used to quantitate the severity of drug-induced damage to the heart. Myofibrillar loss, a major criterion of their scoring system, can involve either thick or thin myofilaments, or both (1). Buja and associates (2) have shown that doxorubicin-induced myofibrillar loss mainly involves thick filaments. Bristow and co-authors, however, do not give a precise definition of this
SANYAL SK, JOHNSON WW. Doxorubicin Cardiomyopathy. Ann Intern Med. 1978;89:136–137. doi: https://doi.org/10.7326/0003-4819-89-1-136
Download citation file:
Published: Ann Intern Med. 1978;89(1):136-137.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use